Development of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome
Publication date:
2019
Publisher version:
Citación:
Nature medicine, 25, p. 423–426 (2019); doi:10.1038/s41591-018-0338-6
Descripción física:
p. 423–426
ISSN:
Patrocinado por:
The Instituto Universitario de Oncología del Principado de Asturias is supported by Fundación Bancaria Caja de Ahorros de Asturias. J.M.P.F. is supported by Ministerio de Economía y Competitividad (MINECO/FEDER: No. SAF2015-64157-R) and Gobierno del Principado de Asturias. C.L.-O. is supported by grants from the European Research Council (ERC-2016-ADG, DeAge), Ministerio de Economía y Competitividad (MINECO/FEDER: Nos. SAF2014-52413-R and SAF2017-87655-R), Instituto de Salud Carlos III (RTICC) and Progeria Research Foundation (No. PRF2016-66). O.S.-F. is recipient of an FPU fellowship. A.R.F. is recipient of a Ramón y Cajal fellowship. The generation of progerin antibody was funded by the Wellcome Trust (No. 098291/Z/12/Z to S.N.).
Collections
- Artículos [37543]
- Bioquímica y Biología Molecular [274]
- Investigaciones y Documentos OpenAIRE [8379]
Files in this item
Métricas
Compartir
